Cormedix Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 13, 2012, reports the final closing of a private placement financing (the "2012 Financing") by Cormedix Inc., a Delaware corporation. The financing involves the sale of Units consisting of Senior Convertible Notes and Warrants to accredited investors.
Key Financial Metrics
- Total Gross Proceeds: $1,324,000 from the sale of 1,324 Units.
- Total Net Proceeds: $1,196,600 (after placement agent fees).
- Final Closing Proceeds: $474,000 gross; $426,600 net.
- Debt Instrument: 9% Senior Convertible Notes with a maturity date of November 13, 2013.
- Interest Rate: 9% per annum, payable quarterly in arrears.
- Prepayment Penalty: 120% of principal plus accrued interest if prepaid under certain conditions.
- Warrant Terms: Five-year warrants to purchase common stock at an initial exercise price of $0.40 per share.
- Placement Agent Fees: Total fees of $127,400 in cash and warrants covering 331,000 shares.
Material Changes
The primary material change is the completion of the 2012 Financing. The Company sold an additional 474 Units in the final closing, bringing the total Units sold to 1,324. This transaction significantly increased the Company's cash position with net proceeds of $1,196,600. The filing also notes that certain directors participated as Purchasers in the final closing.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Funds will be utilized for marketing, manufacturing, rent, utilities, licensing obligations, payroll, working capital, and general corporate purposes.
- Registration Rights: The Company agreed to file a registration statement for the resale of Conversion Shares within 60 days of the final closing and use commercially reasonable efforts to have it declared effective within 120 days.
- Contingencies: If the Company fails to meet registration deadlines, it must pay partial liquidated damages of 1.0% of the purchase price per month, capped at 5% of the aggregate principal amount of the Notes.
- Warrant Redemption: The Company retains the right to redeem Warrants for $0.001 per Warrant if specific market price and volume conditions are met and the shares are eligible for resale.
Investor Verification Checklist
- Verify the effective date of the registration statement for the Conversion Shares to assess potential dilution and liquidity timelines.
- Confirm the Company's ability to service the 9% interest payments on the $1,324,000 principal debt.
- Review the specific terms regarding the prepayment penalty (120% of principal) to understand refinancing or early repayment costs.
- Monitor the stock price relative to the $0.40 warrant exercise price and the 140% threshold required for warrant redemption.
- Check for any subsequent filings regarding the liquidated damages clause if registration deadlines are missed.